NEW YORK, NY / ACCESS Newswire / March 15, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The popular research ...

Larson Financial Group LLC cut its holdings in GSK plc (NYSE:GSK – Free Report) by 52.7% during the fourth quarter, according ...

We recently compiled a list of the 10 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where GSK ...

GSK PLC closed 16.86% short of its 52-week high of £18.24, which the company reached on May 16th.

GSK plc (LON:GSK – Get Free Report)’s share price passed above its 200-day moving average during trading on Wednesday .The stock has a 200-day moving average of GBX 1,444 ($18.73) and traded ...

FDA reviews GSK depemokimab for asthma and CRSwNP, with a decision expected by December 2025. Phase 3 data shows improvements ...

GSK (NYSE:GSK) shares rose for seven straight sessions, as the stock ended 0.7% higher at $40.32 on Monday. The pharmaceutical giant gained over 6.5% in the preceding six sessions. The stock has ...

GSK PLC closed 15.88% below its 52-week high of £18.24, which the company reached on May 16th.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Price Action: GSK stock is up 2.55% at $38.92 at the last check Tuesday. UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get ...

GSK beats Wall Street expectations again, but stock price remains flat despite the success in R&D GSK's revenue was about $10.15 billion in the fourth quarter of 2024, down 0.49% year over year ...